The genetic polymorphism of drug transporters: Functional analysis approaches

Pharmacogenomics

Volumn 5, Issue 1, 2004, Pages 67-99

  Ishikawa, Toshihisa ^a   Tsuji, Akira ^b   Inui, Ken Ichi ^c   Sai, Yoshimichi ^b   Anzai, Naohiko ^d   Wada, Morimasa ^e   Endou, Hitoshi ^d   Sumino, Yasuhiro ^f  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f JPMA   (Japan)

Author keywords

ABC transporter; Drug response; Polymorphism; SNP; Solute carrier family

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABC TRANSPORTER; ANION TRANSPORT PROTEIN; ANTIPORTER; BETA LACTAM ANTIBIOTIC; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; COTRANSPORTER; DAUNORUBICIN; DOXORUBICIN; DRUG METABOLIZING ENZYME; GLUCURONIDE; GLYCOPROTEIN P; IRINOTECAN; METHOTREXATE; MITOXANTRONE; MONOCARBOXYLATE TRANSPORTER; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MULTIDRUG RESISTANCE PROTEIN 6; ORGANIC CATION TRANSPORTER; PEPTIDE TRANSPORTER 1; TACROLIMUS; TETRYLAMMONIUM; TOPOTECAN; UNINDEXED DRUG; VERAPAMIL;

ANALYTIC METHOD; BRAIN; CANCER RESISTANCE; CLASSIFICATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG TRANSPORT; EVIDENCE BASED MEDICINE; FUNCTIONAL ASSESSMENT; GENETIC POLYMORPHISM; HUMAN; INTESTINE; KIDNEY; LIVER; MEDICAL INFORMATION; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOKINETICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SOLUTE; STANDARD; TISSUE TYPES;

EID: 0347136014     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.5.1.67.25683     Document Type: Review

References (192)

1. Drews J: Drug discovery: a historical perspective. Science 287, 1960-1964 (2000).
2. Roses AD: Pharmacogenomics and future drug development and delivery. Lancet 355, 1358-1361 (2000).
3. Pharmacogenomics. Kalow W, Meyer UA, Tyndale RF (Eds), Marcel Dekker, New York (2001).
4. Tsuji A, Tamai I: Carrier-mediated intestinal transport of drugs. Pharm. Res. 13, 963-977 (1996).
5. Zhang L, Brett CM, Giacomini KM: Role of organic cation transporters in drug absorption and elimination. Ann. Rev. Pharmacol. Toxicol. 38, 431-460 (1998).
6. Koepsell H: Organic cation transporters in intestine, kidney; liver, and brain. Ann. Rev. Physiol. 60, 243-266 (1998).
7. Meyer DK, Hooiveld GJ, Schinkel AH et al.: Transport mechanisms for cationic drugs and proteins in kidney, liver and intestine: implication for drug interactions and cell-specific drug delivery. Nephrol. Dial. Transplant. 14, 1-3 (1999).
8. Inui K, Masuda S, Saito H: Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 58, 944-958 (2000).
9. Ayrton A, Morgan P: Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31, 469-497 (2001).
10. Gao B, Meier PJ: Organic anion transport across the chroid plexus. Micrsc. Res. Tech. 52, 60-64 (2001).
11. Kim RB: Transporters in drug disposition. Curr. Opin. Drug Discov. Develop. 3, 94-101 (2002).
12. Borst P, Oude Elferink R: Mammalian ABC transporters in health and disease. Ann. Rev. Biochem. 71, 537-592 (2002).
13. Ishikawa T: Multidrug resistance: genomics of ABC transporters. In: Nature Encyclopedia of the Human Genome (Vol. 4). Cooper DN (Ed.), Nature Publishing Group, London, 154-160 (2003).
14. Wada M, Uchiumi T, Kuwano M: Canalicular multispecific organic anion transporter, ABCC2. In: Membrane Transport Diseases: Molecular Basis of Inherited Transport Defects. Bröer S, Wagner CA (Eds), Kluwer Academic/Plenum Publishers, New York (2003) (In Press).
15. Kanai Y, Endou H: Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity. J. Toxicol. Sci. 28, 1-17 (2003).
16. Ishikawa T, Yoshikawa M: ABC transporters: a new approach to toxicogenomics. In: Toxiogenomics. Inoue T, Pennie WD (Eds), Springer, Tokyo, 109-114 (2003).
17. Smigielski EM, Sirotkin K, Ward M et al.: dbSNP: a database of single nucleotide polymorphisms. Nucleic Acids Res. 28, 352-355 (2000).
18. The International SNP Map Working Group: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928-933 (2001).
19. Gushima, H: Japanese industry takes steps toward genomics-based medicine. Global Outsourcing Rev. 3, 30-37 (2001).
20. Tsuji A: Transporter-mediated drug interactions. Drug Metabol. Pharmacokin. 17, 253-274 (2002).
21. +/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J. Biol. Chem. 270, 6456-6463 (1995).
22. Tamai I, Yabuuchi H, Nezu J et al.: Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett. 419, 107-111 (1997).
23. Yabuuchi H, Tamai I, Nezu J et al.: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J. Pharmacol. Exp. Ther. 289, 768-773 (1999).
24. Tamai I, Nakanishi T, Kobayashi D et al.: Involvement of OCTN1 (SLC22A4) in pH-dependent transport of organic cations. Mol. Pharmaceut. (2004) (In Press).
25. Hagenbuch B, Meier PJ: The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta 1609, 1-18 (2003).
26. Tamai I, Nezu J, Uchino H et al.: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273, 251-260 (2000).
27. Saito S, Iida A, Sekine A et al.: Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population. J. Hum. Genet. 47, 576-584 (2002).
28. Iida A, Saito S, Kekine A et al.: Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-toransporting polypeptides, and three NADH: ubiquinone oxidoreductase flavoproteins. J. Hum. Genet. 46, 668-683 (2001).
29. Nezu J, Tamai I, Oku A et al.: Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat. Genet. 21, 91-94 (1999).
30. Ohashi R, Tamai I, Nezu J et al.: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol. Pharmacol. 59, 358-366 (2001).
31. Ohashi R, Tamai I, Inano A et al.: Studies on functional sites of organic cation/carnitine transporter OCTN2 (SLC22A5) using a Ser467Cys mutant protein. J. Pharmacol. Exp. Ther. 302, 1286-1294 (2002).
32. Nozawa T, Nakajima M, Tamai I et al.: Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302, 804-813 (2002).
33. Tirona RG, Leake BF, Merino G et al.: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276, 35669-35675 (2001).
34. Nishizato Y, Ieiri I, Suzuki H et al.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73, 554-565 (2003).
35. Gorboulev V, Ulzheimer J, Akhoundova A et al.: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 16, 871-881 (1997).
36. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 51, 913-921 (1997).
37. Gründemann D, Gorboulez V, Gambaryan S, Veyhl M, Koepsell H: Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372, 549-552 (1994).
38. Jonker JW, Wagenaar E, Mol CA et al.: Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [S1c22a1]) gene. Mol. Cell Biol. 21, 5471-5477 (2001).
39. Wang D-S, Jonker JW, Kato Y, Kusuhara H, Shinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 302, 510-515 (2002).
40. Kerb R, Brinkmarm U, Chatskaia N et al.: Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 12, 591-595 (2002).
41. Shu Y, Leabman MK, Feng B et al.: Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl. Acad. Sci. USA 100, 5902-5907 (2003).
42. Hirakawa M, Tanaka T, Hashimoto Y, Kuroda M, Takagi T, Nakamura Y: JSNP: a database of common gene variations in the Japanese population. Nucleic Acids Res. 30, 158-162 (2002).
43. Sakata T, Anzai N, Shin HJ et al.: Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem. Biophys. Res. Commun. (2004) (In Press).
44. Burckhardt G, Wolff NA: Structure of renal organic anion and cation transporters. Am. J. Physiol. Renal Physiol. 278, F853-F866 (2000).
45. Dresser MJ, Gray AT, Giacomini KM: Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1). J Pharmacol. Exp. Ther. 292, 1146-1152 (2000).
46. Takeuchi A, Motohashi H, Okuda M, Inui K: Decreased function of genetic variants, Pro283Keu and Arg287Gly, in human organic cation transporter hOCT1. Drug Metabol. Pharmacokin. 18, 409-412 (2003).
47. Grantham R: Amino acid difference formula to help explain protein evolution. Science 185, 862-864 (1974).
48. Henikoff S, Henikoff JG: Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. USA 89, 10915-10919 (1992).
49. Wang D-S, Jonker JW, Kato Y, Kusuhara H, Shinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 302, 510-515 (2002).
50. Klein I, Sarkadi B, Váradi A: An inventory of the human ABC proteins. Biochim. Biophys. Acta 1461, 237-262 (1999).
51. Dean M, Rzhetsky A, Allikmets R: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156-1166 (2001).
52. Higgins CF: ABC transporters: from microorganisms to man. Ann. Rev. Cell Biol. 8, 67-113 (1992).
53. Ling V: Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 40, S3-S8 (1997).
54. Ambudkar SV, Dey S, Hrycyna CA et al.: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Ann. Rev. Pharmacol. Toxicol. 39, 361-398 (1999).
55. Schinkel AH, Smit JJ, van Tellingcn O et al.: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502 (1994).
56. Rao US: Mutation of glycine 185 to valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells. J. Biol. Chem. 270, 6686-6690 (1995).
57. Kerb R, Hoffmeyer S, Brinkmann U: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2, 51-64 (2001).
58. Sparreboom A, Danesi R, Ando Y et al.: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resistance Update 6, 71-84 (2003).
59. Saito S, Iida A, Sekine A et al.: Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese populations. J. Hum. Genet. 47, 38-50 (2002).
60. Schwab M, Eichelbaum M, Fromm MF: Genetic polymorphisms of the human MDR1 drug transporter. Ann. Rev. Pharmacol. Toxicol. 43, 285-307 (2003).
61. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
62. Weinshilboum R: Inheritance and drug response. J. Engl. J. Med. 348, 529-537 (2003).
63. Itoda M, Saito Y, Komamura K et al.: Twelve novel single nucleotide polymorphisms in ABCB1/MDR1 among Japanese patients with ventricular tachycardia who were administered amiodarone. Drug Metab. Pharmacokin. 17, 566-571 (2002).
64. Anglicheau D, Verstuyft C, Laurent-Puig P et al.: Association of multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolims dose requirement in renal transplant recipients. J. Am. Soc. Nephrol. 14, 1889-1896 (2003).
65. Kafka A, Sauer G, Jaeger C et al.: Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int. J. Oncol. 22, 1117-1121 (2003).
66. Brumme ZL, Dong WW, Chan KL et al.: Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy resonse. AIDS 17, 201-208 (2003).
67. Macphee IA, Fredericks S, Tai T et al.: Tacrolims pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74, 1486-1489 (2002).
68. Johne A, Kopke Y, Gerloff T et al.: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72, 584-594 (2002).
69. Siegmund W, Ludwig K, Giessmann T et al.: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. 72, 572-583 (2002).
70. Kim RB: MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 12, 425-427 (2002).
71. Roberts RL, Joyce PR, Mulder RT et al.: A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2, 191-196 (2002).
72. + hematopoietic stem cells. Haematologica 87, 564-568 (2002).
73. Hoffmeyer S, Burk O, Von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Soc. USA 97, 3473-3478 (2000).
74. Balram C, Sharma A, Sivathasan C et al.: Frequence of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br. J. Clin. Pharmacol. 56, 78-83 (2003).
75. Tang K, Ngoi SM, Gwee PC et al.: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12, 437-450 (2002).
76. Illmer T, Schuler US, Thiede C et al.: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 62, 4955-4962 (2002).
77. Drescher S, Scheffeler E, Hitzl M et al.: MDR1 gene polymorphisms and disposition of the P-glycoprotein substare fexofenadine. Br. J. Clin. Pharmacol. 53, 526-534 (2002).
78. Hitzl M, Drescher S, Van der Kuip H et al.: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11, 293-298 (2001).
79. Fellay J, Marzolini C, Meaden ER et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetic study. Lancet 359, 30-36 (2002).
80. Nakamura T, Sakaeda T, Horinouchi M et al.: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. 71, 297-303 (2002).
81. Moriya Y, Nakamura T, Horinouchi M et al.: Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNAs expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. 25, 1356-1359 (2002).
82. Van der Heiden LP, Van der Heuvel MM, Weimer E et al.: MDR-1 C3435T gene polymorphisms does not correlate with P-glycoprotein expression and function in acute myeloid leukemia. Clin. Pharmacol. Ther. 73, 58 (Abstract) (2003).
83. Desai DG, Maruyama N, Lantz M et al.: The functional change of P-glycoprotein on lymphocytes under induction condition as a function of MDR1 polymorphisms. Clin. Pharmacol. Ther. 37, 13 (Abstract) (2003).
84. Von Ahsen N, Richter M, Grupp C et al.: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promotor polymophism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. 47, 1048-1052 (2001).
85. Min DI, Elingrod VL: C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. 24, 400-404 (2002).
86. Chowbay B, Cumaraswamy S, Cheng YB et al.: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13, 89-95 (2003).
87. Van Schaik R, Hesselink DA, Van der Heiden IP et al.: Tacrolims, but not cyclosporin, drug levels are correlated with CYP3A5*3 and CYP3A4*1B genotype no correlation with the MDR-1 C3435T polymorphism. Clin. Pharmacol. Ther. 73, 56 (Abstract) (2003).
88. Putnam W, Desai DG, Huang Y et al.: The effect of induction condition and MDR1 genotypes on dicloxacillin pharmacokinetics. Clin. Pharmacol. Ther. 73, 57 (Abstract) (2003).
89. Becquemont L, Verstuyft C, Kerb R et al.: Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol. Ther. 70, 311-316 (2001).
90. Sakaeda T, Nakamura T, Horinouchi M et al.: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 18, 1400-1404 (2001).
91. Gerloff T, Schaefer M, Johne A et al.: MDR1 genotypes do not influence the absorption of a single oral dose of 1mg digoxin in healthy white males. Br. J. Pharmacol. 54, 610-616 (2002).
92. Kurata Y, Ieiri I, Kimura M et al.: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther. 72, 209-219 (2002).
93. Verstuyft C, Strabach S, El Morabet H et al.: Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin. Pharmacol. Ther. 73, 51-60 (2003).
94. Goh BC, Lee SC, Wang LZ et al.: Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. 20, 3683-3690 (2002).
95. Goto M, Masuda S, Saito H et al.: C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12, 451-457 (2002).
96. Yamauchi A, Ieiri I, Kataoka Y et al.: Neurotoxicity induced by tacrolimus after liver transplantation: relation to polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74, 571-572 (2002).
97. Mathijssen RH, Loos WJ, Verweij J et al.: Pharmacokinetic and pharmacogenetic analysis of irinotecan (CPT-11) in combination with R115777. Eur. J. Cancer 38, S44 (Abstract) (2002).
98. Kimchi-Sarfaty C, Griber JJ, Gottesman MM: Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 62, 1-6 (2002).
99. Mickley LA, Lee JS, Weng Z et al.: Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unslected and drug-selected cell lines, and human tumors. Blood 91, 1749-1756 (1998).
100. Kim RB, Leake BF, Choo EF et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70, 189-199 (2001).
101. Carter SG, Karl DW: Inorganic phosphate assay with malachite green: an improvement and evaluation. J. Biochem. Biophys. Methods 7, 7-13 (1982).
102. Sarkadi B, Price EM, Boucher RC et al.: Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem. 267, 4854-4858 (1992).
103. Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92, 1295-1302 (2000).
104. Ishikawa T, Kuo MT, Furuta K, Suzuki M: The human multidrug resistance-associated protein (MRP) gene family: from biological function to drug molecular design. Clin. Chem. Lab. Med. 38, 893-897 (2000).
105. König J, Nies AT, Cui Y, Keppler D: MRP2, the apical export pump for anionic conjugates. In: ABC Proteins: from Bacteria to Man. Holland IB, Cole SPC, Kuchler K, Higgins CF (Eds), Academic Press, Amsterdam, 423-443 (2003).
106. Taniguchi K, Wada M, Kohno K et al.: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56, 4124-4129 (1996).
107. Buchler M, Konig J, Brom M et al.: cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. 271, 15091-15098 (1996).
108. Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu T, Sugiyama Y: Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR rats. Am. J. Physiol. 35, G16-G22 (1997).
109. Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL: Congenital jaundice in rats with a mutation in a multidrug resistance associated protein gene. Science 271, 1126-1128 (1996).
110. Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T: Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem. Biophys. Res. Commun. 247, 859-863 (1998).
111. Loe DW, Deeley RG, Cole SP: Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 58, 5130-5136 (1998).
112. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D: Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 56, 988-994 (1996).
113. Ishikawa T: The ATP-dependent glutathione S-conjugate export pump. Trends Biochem. Sci. 17, 463-468 (1992).
114. Bakos E, Evers R, Sinkule JA, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol. 57, 760-768 (2000).
115. Loe DW, Almquist KC, Deeley RG, Cole SPC: Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles: demonstration of glutathione-dependent vincristine transport. J. Biol. Chem. 271, 9675-9682 (1996).
116. Loe DW, Almquist KC, Cole SPC, Deeley RG: ATP-dependent 17 β-estradiol 17-(β-D-glucuronide) transport by multidrug resistance protein: inhibition by cholestatic steroids. J. Biol. Chem. 271, 9683-9689 (1996).
117. Loe DW, Stewart RK, Massey TE, Deeley RG, Cole SPC: ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the MRP gene. Mol. Pharmacol. 51, 1034-1041 (1997).
118. Ishikawa T, Müller M, Klünemann C et al.: ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates. J. Biol. Chem. 265, 19279-19286 (1990).
119. Evers R, Cnubben NH, Wijnholds J, van Deemter L, van Bladeren PJ, Borst P. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett. 419, 112-116 (1997).
120. Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J: Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim. Biophys. Acta 1326, 12-22 (1997).
121. Hooijberg JH, Broxterman HJ, Heijn M, Fles DL, Lankelma J, Pinedo HM: Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. FEBS Lett. 413, 344-348 (1997).
122. Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchell B, Keppler D: ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem. J. 327, 305-310 (1997).
123. Toh S, Wada M, Uchiumi T et al.: Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Hum. Genet. 64, 739-746 (1999).
124. Frank M, Doss M, de Carvalho DG: Diagnostic and pathogenetic implications of urinary coproporphyrin excretion in the Dubin-Johnson syndrome. Hepatogastroenterology 37, 147-151 (1990).
125. Takino T, Takahashi T, Okuno T: Clinical study of the constitutional hyperbilirubinemia in Japan. A nationwide survey between. 1970 and 1974. Jpn. J. Gastroenterol. 74, 1518-1528 (1977).
126. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K: Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11, 175-184 (2001).
127. Saito S, Iida A, Sekine A et al.: Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR). J. Hum. Genet. 47, 147-171 (2002).
128. Suzuki H, Sugiyama Y: Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliver. Rev. 54, 1311-1331 (2002).
129. Kartenbeck J, Leuschner U, Mayer R, Keppler D: Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 23, 1061-1066 (1996).
130. Keppler D, Kartenbeck J: The canalicular conjugate export pump encoded by the cmrp/cmoat gene. Prog. Liver Dis. 14, 55-67 (1996).
131. Paulusma CC, Kool M, Bosma PJ, Scheffer GL, Ter Borg F, Scheper RJ: Mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 25, 1539-1542 (1997).
132. Tsujii H, Konig J, Rost D, Stockel B, Leuschner U, Keppler D: Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. Gastroenterology 117, 653-660 (1999).
133. Wada M, Toh S, Taniguchi K et al.: Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum. Mol. Genet. 7, 203-207 (1998).
134. Tate G, Li M, Suzuki T, Mitsuya T: A new mutation of the ATP-binding cassette, sub-family C, member 2 (ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome. Genes Genet. Syst. 77, 117-121 (2002).
135. Keitel V, Kartenbeck J, Nies AT, Spring H, Brom M, Keppler D: Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 32, 1317-1328 (2000).
136. Mor-Cohen R, Zivelin A, Rosenberg N, Shani M, Muallem S, Seligsohn U: Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J. Biol. Chem. 276, 36923-36930 (2001).
137. Hashimoto K, Uchiumi T, Konno T et al.: Trafficking-defect and functional-defect by mutations of the ATP-binding domains in multidrug resistance protein 2 in patients with Dubin-Johnson syndrome. Hepatology 36, 1236-1245 (2002).
138. Schwartz AL, Ciechanover A: The ubiquitin-proteasome pathway and pathogenesis of human diseases. Ann. Rev. Med. 50, 57-74 (1999).
139. Senior AE, al-Shawi MK, Urbatsch IL: The catalytic cycle of P-glycoprotein. FEBS Lett. 377, 285-289 (1995).
140. Urbatsch IL, Sankaran B, Weber J, Senior AE: P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. J. Biol. Chem. 270, 19383-19390 (1995).
141. Gao M, Cui HR, Loe DW et al.: Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1. J. Biol. Chem. 275, 13098-13108 (2000).
142. Nagata K, Nishitani M, Matsuo M, Kioka N, Amachi T, Ueda K: Nonequivalent nucleotide trapping in the two nucleotide binding folds of the human multidrug resistance protein MRP1. J. Biol. Chem. 275, 17626-17630 (2000).
143. Hung LW, Wang IX, Nikaido K, Liu PQ, Ames GF, Kim SH: Crystal structure of the ATP-binding subunit of an ABC transporter. Nature 396, 703-707 (1998).
144. Dork T, Mekus F, Schmidt K et al.: Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. Hum. Genet. 94, 533-542 (1994).
145. Diederichs K, Diez J, Greller G et al.: Crystal structure of MalK, the ATPase subunit of the trehalose/maltose ABC transporter of the archaeon Thermococcus litoralis. EMBO J. 19, 5951-5961 (2000).
146. Kajihara S, Hisatomi A, Mizuta T et al.: A splice mutation in the human canalicular multispecific organic anion transporter gene causes Dubin-Johnson syndrome. Biochem. Biophys. Res. Commun. 253, 454-457 (1998).
147. Doyle LA, Yang W, Abruzzo LV et al.: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 95, 15665-15670 (1998).
148. Allikmets R, Schriml LM, Hutchinson A et al.: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58, 5337-5339 (1998).
149. Miyake K, Mickley L, Litman T et al.: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59, 8-13 (1999).
150. Schmitz G, Langmann T, Heimerl S: Role of ABCG1 and other ABCG family members in lipid metabolism. J. Lipid Res. 42, 1513-1520 (2001).
151. Kage K, Tsukahara S, Sugiyama T et al.: Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int. J. Cancer 97, 626-630 (2002).
152. Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD: Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim. Biophys. Acta 1520, 234-241. (2001).
153. Maliepaard M, Scheffer GL, Faneyte IF et al.: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61, 3458-3464 (2001).
154. Zhou S, Schuetz JD, Bunting KD et al.: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7, 1028-1034 (2001).
155. Jonker JW, Buitelaar M, Wagenaar E et al.: The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. USA 99, 15649-15654 (2002).
156. Maliepaard M, van Gastelen MA, de Jong LA et al.: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 59, 4559-4563 (1999).
157. Ross DD, Yang W, Abruzzo LV et al.: Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst. 91, 429-433 (1999).
158. Brangi M, Litman T, Ciotti M et al.: Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 59, 5938-5946 (1999).
159. Litman T, Brangi M, Hudson E et al.: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. 113, 2011-2021 (2000).
160. Nakagawa R, Hara,Y, Arakawa H, Nishimura S, Komatani H: ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport. Biochem. Biophys. Res. Commun. 299, 669-675 (2002).
161. Ross DD: Novel mechanisms of drug resistance in leukemia. Leukemia 14, 467-473 (2000).
162. Van der Kolk DM, Vellenga E, Scheffer GL et al.: Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 99, 3763-3770 (2002).
163. Kawabata S, Oka M, Shiozawa K et al.: Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem. Biophys. Res. Commun. 280, 1216-1223 (2001).
164. Nakatomi Y, Yoshikawa M, Oka M et al.: Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem. Biophys. Res. Commun. 288, 827-832 (2001).
165. Honjo Y, Hrycyna, CA, Yan Q-W et al.: Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 61, 6635-6639 (2001).
166. Komatani H, Kotani H, Hara Y et al.: Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res. 61, 2827-2832 (2001).
167. Mitomo H, Kato R, Ito A et al.: A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of Arg-482 in methotrexate transport. Biochem. J. 373, 767-774 (2003).
168. Chen A-S, Robey RW, Belinsky MG et al.: transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2: effect of acquired mutations at R482 on methotrexate transport. Cancer Res. 63, 4048-4054 (2003).
169. Volk EL, Schneider E: Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 63, 5538-5543 (2003).
170. Volk EL, Farley, KM, Wu Y, Li F, Robey RW, Schneider E: Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 62, 5035-5040 (2002).
171. Honjo Y, Morisaki K, Huff LM et al.: Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol. Ther. 1, 696-702 (2002).
172. Iida A, Saito S, Sekine A et al.: Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J. Hum. Genet. 47, 285-310 (2002).
173. Imai Y, Nakane M, Kage K et al.: C421A polymorphism in human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 1, 611-616 (2002).
174. Itoda M, Saito Y, Shirao K et al.: Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotecan. Drug. Metab. Pharmacokin. 18, 212-217 (2003).
175. Chowbay B, Kibat C, Zhou Q, Li HH, Lee EJD: Genetic polymorphism and allelic association in the ABCG2 in three distinct Asian population. Pharmacogenetics (2003) (In Press).
176. Zamber CP, Lamba JK, Yasuda K et al.: Natural allelic variations of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13, 19-28 (2003).
177. Bäckström G, Taipalensuu J, Melhus H et al.: Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur. J. Pharm. Sci. 18, 359-364 (2003).
178. Ishikawa T, Kasamtsu S, Hagiwara Y et al.: Expression and functional characterization of human ABC transporter ABCG2 variants in insect cells. Drug Metabol. Pharamcokin. 18, 194-202 (2003).
179. 2+-dependent cardiac transport system for glutathione S-conjugates: a study using heart sarcolemma vesicles. J. Biol. Chem. 264, 17343-17348 (1989).
180. Yoshikawa M, Ikegami Y, Sano K et al.: Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J. Exp. Ther. Oncol. (2004) (In Press).
181. Fromm MF: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug. Deliv. Rev. 54, 1295-1310 (2002).
182. Siddiqui A, Kerb R, Weale ME et al.: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348, 1442-1448 (2003).
183. Morita N, Yasumori T, Nakayama K: Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem. Pharmacol. 65, 1843-1852 (2003).
184. Efferth T, Sauerbrey A, Steinbach D et al.: Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int. J. Oncol. 23, 509-517 (2003).
185. Yates CR, Zhang W, Song P et al.: The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol. 43, 555-564 (2003).
186. Sakaeda T, Nakamura T, Okumura K: Pharmacogenomics of MDR1 and its impact on the pharmacokinetics and phrmacoynamics of drugs. Pharmacogenomics 4, 397-410 (2003).
187. Kroetz DL, Pauli-Magnus C, Hodges LM et al.: Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter. Pharmacogenetics 13, 481-494 (2003).
188. Westphal K, Weinbrenner A, Zschiesche M et al.: Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68, 345-355 (2000).
189. Dürr D, Stieger B, Kullak-Ublick GA et al.: St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68, 598-604 (2000).
190. Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui K: Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin. Pharmacol. Ther. 68, 98-103 (2000).
191. Hashida T, Masuda S, Uemoto S et al.: Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin. Pharmacol. Ther. 69, 308-316 (2001).
192. Chawla A, Repa JJ, Evans RM, Mangeldorf DJ: Nuclear receptors and lipid physiology: opening the X-files. Science 294, 1866-1870 (2001).